Why the study?
Does high-dose lisinopril reduce morbidity and mortality compared to low-dose lisinopril in patients with chronic heart failure?
Population
Patients with New York Heart Association class II to IV heart failure and an ejection fraction ≤30%
Comparison
High doses of lisinopril added to background… vs Low doses of lisinopril added to background…
Design
RCT, Randomly assigned, Double-blind
Follow-up
39 to 58 months
Key result
High doses of lisinopril led to 12% lower risk of death or hospitalization and 24% fewer heart failure hospitalizations compared to low doses.
Authors
Loading...
High-dose lisinopril reduces death or hospitalization in chronic HF; confirms prior evidence favoring higher ACE inhibitor targets.
Does high-dose lisinopril reduce morbidity and mortality compared to low-dose lisinopril in patients with chronic heart failure?
High-dose lisinopril significantly reduces the combined risk of death or hospitalization compared to low-dose lisinopril in patients with chronic heart failure, supporting the use of higher target doses.
Packer et al. (1999) studied this question. High doses of lisinopril led to 12% lower risk of death or hospitalization and 24% fewer heart failure hospitalizations compared to low doses.